Infographic | September 15, 2020

Reasons CDMOs Lose Bioprocessing Bids

Source: ISR Reports

In Q2 2020, ISR asked 100 respondents who outsource bioprocessing what is the main reason a CDMO may lose the bid for an outsourced bioprocessing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 32% of respondents’ votes. To learn more, follow the link to the Bioprocessing Trends and Outsourcing Dynamics: 2020-2025 report preview.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online